Evidence map›Paper›PMID 39306823›Full record

ArticleCell biochemistry and biophysics2025

Triethylammonium Salts of Dicoumarol: Synthesis, Characterization, Human Antiglioblastoma, Antimicrobial and Antioxidant Studies.

Sadia Rehman, Muhammad Ikram, Afzal Khan, Adnan Khan, Farzia, Rizwan Khan, Mutasem Omar Sinnokrot, Vinay K Puduvalli, Ayub Jadoon

Abstract read
PubMed Publisher
In one paragraph

Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sadia RehmanDepartment of Chemistry, Abdul Wali Khan University, Mardan, Pakistan. sadia@awkum.edu.pk.
Muhammad IkramDepartment of Chemistry, Abdul Wali Khan University, Mardan, Pakistan.
Afzal KhanDepartment of Chemistry, Abdul Wali Khan University, Mardan, Pakistan.
Adnan KhanSchool of Physics & the Key Laboratory of Weak Light Nonlinear Photonics, Ministry of Education, Nankai University, Tianjin, 300071, PR China.
FarziaDepartment of Chemistry, Abdul Wali Khan University, Mardan, Pakistan.
Rizwan KhanDepartment of Zoology, Abdul Wali Khan University, Mardan, Pakistan.
Mutasem Omar SinnokrotCollege of Arts and Sciences, American University of IraqBaghdad, Airport Road, Baghdad, Iraq.
Vinay K PuduvalliDepartment of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ayub JadoonDepartment of Microbiology, Abbotabad University of Science and Technology, Abbotabad, Pakistan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most typical primary brain tumor, glioblastoma multiforme (GBM), has a dismal prognosis. They are removed through arduous, potentially fatal operations. The primary cause of tumor recurrence following surgery is glioblastoma stem cells (GSCs). In order to combat the recurrent glioblastoma malignant cells, medications have been developed. Chemotherapies now in use are expensive and encounter resistance. To combat inherent and developed resistance, new and powerful chemotherapeutics are being synthesized. In this regard, dicoumarols were deprotonated by triethylamine to produce corresponding salts which are reported and used for the first time for human antiglioblastoma activity. Spectroscopic characterizations like

Indexed as

Anti-Infective AgentsAntineoplastic AgentsAntioxidantsGlioblastomaApoptosisBrain NeoplasmsCell Line, TumorHumansSaltsAnti-Infective AgentsAntineoplastic AgentsAntioxidantsSaltsAntimicrobial and antifungalDicoumarolDPPH free radical scavengerHuman glioblastoma drug

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.